thalidomide has been researched along with Cutaneous T-Cell Lymphoma in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "EORTC 21081 was a randomized phase III study of observation alone versus lenalidomide maintenance (25 mg po for 21 days) after debulking therapy in patients with advanced-stage cutaneous T-cell lymphomas (CTCLs)." | 9.24 | A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. ( Bagot, M; Beylot-Barry, M; Chaby, G; Cowan, R; Dalle, S; Fox, CP; Hasan, B; Jonak, C; Knobler, R; Marreaud, S; Morris, S; Quaglino, P; Ritchie, D; Romero, PLO; Scarisbrick, J; Servitje, O; Shah, E; Stadler, R; Väkevä, L; Vermeer, MH; Whittaker, S, 2017) |
| "EORTC 21081 was a randomized phase III study of observation alone versus lenalidomide maintenance (25 mg po for 21 days) after debulking therapy in patients with advanced-stage cutaneous T-cell lymphomas (CTCLs)." | 5.24 | A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. ( Bagot, M; Beylot-Barry, M; Chaby, G; Cowan, R; Dalle, S; Fox, CP; Hasan, B; Jonak, C; Knobler, R; Marreaud, S; Morris, S; Quaglino, P; Ritchie, D; Romero, PLO; Scarisbrick, J; Servitje, O; Shah, E; Stadler, R; Väkevä, L; Vermeer, MH; Whittaker, S, 2017) |
| "Thalidomide and analogues are a class of immunomodulatory drugs or IMiDS." | 2.46 | Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. ( Ladizinski, B; Levis, WR; Sanchez, MR; Shannon, EJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagot, M | 1 |
| Hasan, B | 1 |
| Whittaker, S | 1 |
| Beylot-Barry, M | 1 |
| Knobler, R | 1 |
| Shah, E | 1 |
| Marreaud, S | 1 |
| Morris, S | 1 |
| Dalle, S | 1 |
| Servitje, O | 1 |
| Cowan, R | 1 |
| Väkevä, L | 1 |
| Chaby, G | 1 |
| Jonak, C | 1 |
| Fox, CP | 1 |
| Ritchie, D | 1 |
| Vermeer, MH | 1 |
| Stadler, R | 1 |
| Romero, PLO | 1 |
| Scarisbrick, J | 1 |
| Quaglino, P | 1 |
| Quintanilla-Martinez, L | 1 |
| Ridaura, C | 1 |
| Nagl, F | 1 |
| Sáez-de-Ocariz, M | 1 |
| Durán-McKinster, C | 1 |
| Ruiz-Maldonado, R | 1 |
| Alderete, G | 1 |
| Grube, P | 1 |
| Lome-Maldonado, C | 1 |
| Bonzheim, I | 1 |
| Fend, F | 1 |
| Beltrán, BE | 1 |
| Maza, I | 1 |
| Moisés-Alfaro, CB | 1 |
| Vasquez, L | 1 |
| Quiñones, P | 1 |
| Morales, D | 1 |
| Sánchez, G | 1 |
| Paredes, G | 1 |
| Oscanoa, M | 1 |
| Gerónimo, J | 1 |
| Miranda, RN | 1 |
| Castillo, JJ | 1 |
| Ladizinski, B | 1 |
| Shannon, EJ | 1 |
| Sanchez, MR | 1 |
| Levis, WR | 1 |
| Oxberry, SG | 1 |
| Johnson, MJ | 1 |
1 review available for thalidomide and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
Topics: Behcet Syndrome; Dermatitis; Erythema Nodosum; Humans; Immunomodulation; Lupus Erythematosus, Cutane | 2010 |
1 trial available for thalidomide and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs.
Topics: Aged; Angiogenesis Inhibitors; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free | 2017 |
3 other studies available for thalidomide and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma.
Topics: Adolescent; Child; Child, Preschool; Epstein-Barr Virus Infections; Female; Follow-Up Studies; Herpe | 2013 |
Thalidomide for the treatment of hydroa vacciniforme-like lymphoma: report of four pediatric cases from Peru.
Topics: Adolescent; Child; Female; Humans; Hydroa Vacciniforme; Immunosuppressive Agents; Lymphoma, T-Cell, | 2014 |
Response to thalidomide in chemotherapy-resistant cutaneous T-cell lymphoma.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Lymphoma, T-Cell, Cutaneous; Thalidomide | 2006 |